| Oct 31 |
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis
|
| Oct 15 |
Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting
|
| Oct 10 |
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)
|
| Oct 8 |
Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
|
| Sep 25 |
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
|
| Sep 16 |
Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies
|
| Sep 5 |
Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification
|
| Aug 19 |
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
| Aug 13 |
Palisade Bio GAAP EPS of -$3.32
|
| Aug 13 |
Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
|
